Updated time: 2021-02-23 17:12:53
28A-1071214
2021-02-23
PCT and TW patents pending.
Human pluripotent stem cells (hPSCs) has tremendous potential in regenerative medicine due to its pluripotency (differentiate into almost all cell types) and immortalized ability. An important safety concern of PSCs is the tumorigenic risk. Here we demonstrate cholesterol inhibitors can eliminate undifferentiated hPSCs. We will test whether cholesterol inhibitors will spare hPSC- derived mesenchymal stem cells, neuron, and hepatocytes. Furthermore, we will test in mice experiments if cholesterol inhibitors can prevent teratoma. This is the first cholesterol inhibitors that can treated patients for long term that have cytotoxicity in undifferentiated hPSCs. One previous report claim that cholesterol inhibitors can kill undifferentiated mouse ESCs. However, the killing of hPSCs are through different mechanism. Cholesterol inhibitors can eliminate PSCs in a common cE8 culture medium.
- The only long efficacy safe FDA approved drug that can prevent the tumorigenicity of hPSCs.
- cheap.
- The cytotoxicity of cholesterol inhibitors in hPSCs is very effective.
- Cholesterol inhibitors may not affect the viability or function of the hPSC-derived cells.
Regenerative medicine. It can be applied to cell therapy that use hPSCs -derived cells.
It is also possible to treat the patients with cholesterol inhibitors to prevent or treat teratoma when they transplanted with hPSC derived cells.
Joyce Jean Lu, Wei-Ju Chen
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A method to eliminate oncogenic undifferentiated human pluripotent stem cells by cholesterol inhibitor